000 02573nam a22006977a 4500
008 191010s20192019 xxu||||| |||| 00| 0 eng d
022 _a1878-0938
024 _a10.1016/j.carrev.2019.07.016 [doi]
024 _aS1553-8389(19)30428-2 [pii]
040 _aOvid MEDLINE(R)
099 _a31447315
245 _aOverview of the 2018 US Food and Drug Administration Circulatory System Devices Panel Meeting on Device-Based Therapies for hypertension.
251 _aCardiovascular Revascularization Medicine. 20(10):891-896, 2019 Oct.
252 _aCardiovasc Revasc Med. 20(10):891-896, 2019 Oct.
252 _zCardiovasc Revasc Med. 2019 Jul 17
253 _aCardiovascular revascularization medicine : including molecular interventions
260 _c2019
260 _fFY2020
265 _saheadofprint
265 _sppublish
266 _d2019-10-10
268 _aCardiovascular Revascularization Medicine. 2019 Jul 17
501 _aAvailable in print through MWHC library: 2002 - present
546 _aEnglish
650 _a*Autonomic Denervation/is [Instrumentation]
650 _a*Blood Pressure
650 _a*Catheter Ablation/is [Instrumentation]
650 _a*Device Approval
650 _a*Hypertension/th [Therapy]
650 _a*Kidney/bs [Blood Supply]
650 _a*Renal Artery/ir [Innervation]
650 _a*United States Food and Drug Administration
650 _aAntihypertensive Agents/tu [Therapeutic Use]
650 _aAutonomic Denervation/ae [Adverse Effects]
650 _aBlood Pressure/de [Drug Effects]
650 _aCatheter Ablation/ae [Adverse Effects]
650 _aDrug Resistance
650 _aEquipment Design
650 _aEquipment Safety
650 _aHumans
650 _aHypertension/di [Diagnosis]
650 _aHypertension/pp [Physiopathology]
650 _aPatient Safety
650 _aRisk Assessment
650 _aRisk Factors
650 _aTreatment Outcome
650 _aUnited States
651 _aMedStar Heart & Vascular Institute
657 _aJournal Article
700 _aChen, Yuefeng
700 _aDan, Kazuhiro
700 _aKhalid, Nauman
700 _aRogers, Toby
700 _aShlofmitz, Evan
700 _aTorguson, Rebecca
700 _aWaksman, Ron
700 _aWeintraub, William S
790 _aChen Y, Dan K, Khalid N, Rogers T, Shlofmitz E, Torguson R, Waksman R, Weintraub WS
856 _uhttps://dx.doi.org/10.1016/j.carrev.2019.07.016
_zhttps://dx.doi.org/10.1016/j.carrev.2019.07.016
942 _cART
_dArticle
999 _c4611
_d4611